Financial Reports Latest Updates Industry Maps Economic Calendar

Stoke Therapeutics, Inc. (STOK) Annual Reports

Q: Where can I read Stoke Therapeutics, Inc. (STOK) annual reports?

Every year on this page links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser. 3 filings are currently indexed.

Q: What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer; a 20-F is filed by foreign private issuers (Taiwanese companies with US ADRs, such as TSMC, file 20-F). A 40-F applies to Canadian issuers under the MJDS.

Stoke Therapeutics, Inc. is listed on Nasdaq, classified by the SEC under Pharmaceutical Preparations (SIC 2834). This page indexes 3 annual reports, each linking to the full text on the SEC's EDGAR system.

Company profile

Exchange： Nasdaq
Fiscal year end： 12/31
SEC CIK： 1623526 →

Website：Official site ↗

Financial Highlights

FY2026 Q3 (quarterly, ended 2026-09-30)
	Current	Prior year	YoY
Revenue	$11.3M	$10.6M	+5.9%
Operating income	$-77.3M	$-43.1M	-79.4%
Net income	$-73.6M	$-38.3M	-92.0%
EPS (diluted)	$-1.08	$-0.65	-66.2%

Source: SEC EDGAR (XBRL company facts)

Financial history

Revenue & profit

Quarterly · In mn (USD)

Revenue 11.3 mn Net income -73.6 mn

Show table：Income statement

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Revenue	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.00	3.23	2.91	3.27	5.15	-2.48	3.31	2.80	4.22	4.83	4.89	22.6	159	13.8	10.6	1.40	6.23	9.32	11.3
Operating income	-1.91	-3.01	-3.32	-4.54	-6.32	-8.44	-9.84	-11.1	-11.7	-13.0	-13.7	-14.6	-16.8	-22.0	-22.7	-24.5	-24.8	-25.2	-27.1	-27.2	-24.7	-33.3	-27.2	-29.6	-28.4	-29.3	-30.0	-13.7	111	-27.3	-43.1	-61.4	-53.4	-65.4	-77.3
Net income	-1.91	-3.01	-3.32	-4.28	-5.74	-7.82	-8.60	-10.2	-11.0	-13.0	-13.7	-14.6	-16.8	-22.0	-22.6	-24.4	-24.6	-24.6	-26.1	-25.6	-22.5	-30.6	-24.5	-27.0	-26.4	-25.7	-26.4	-10.5	113	-23.5	-38.4	-57.9	-50.0	-61.6	-73.6

Balance sheet

Quarterly · In mn (USD)

Total assets 407 mn Total liabilities 54.1 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Current assets	—	—	—	106	—	244	237	226	216	206	195	294	275	260	245	229	306	289	265	244	270	246	230	215	193	297	254	233	376	270	272	306	367	323	354
Total assets	—	—	—	108	—	246	239	229	221	210	200	298	279	264	254	239	316	301	278	256	282	257	240	228	205	308	293	272	407	385	360	418	443	394	407
Current liabilities	—	—	—	2.47	—	4.82	4.92	4.10	5.46	5.81	6.74	11.4	6.11	8.20	11.9	17.1	22.9	27.6	28.8	31.4	31.5	21.8	25.2	30.8	35.6	44.5	49.9	40.1	44.7	38.7	41.7	57.9	40.8	41.9	49.0
Total liabilities	—	—	—	2.47	—	4.84	5.14	4.32	6.50	6.81	7.40	11.8	6.44	9.38	16.3	21.1	76.0	77.1	73.5	71.2	68.0	66.7	66.9	68.8	64.8	65.0	61.2	42.5	56.8	49.6	52.2	66.0	48.4	48.4	54.1
Equity	12.2	9.29	19.4	105	99.6	242	234	224	214	203	193	286	272	255	238	218	240	224	204	185	214	190	173	160	140	243	232	229	350	335	308	352	395	346	353

Cash flow

Quarterly · In mn (USD)

Operating -62.7 mn Investing -10.2 mn Financing 70.2 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Operating	—	-4.41	-3.04	-3.51	-6.53	-6.27	-8.05	-10.2	-10.8	-9.65	-10.9	-10.9	-20.1	-15.8	-14.7	-16.3	32.5	-19.9	-22.1	-22.4	-21.4	-21.8	-17.3	-20.6	-24.6	-17.5	-21.6	-23.2	132	-25.4	-30.4	-30.4	-60.6	-56.6	-62.7
Investing	—	-0.33	-0.52	-0.08	-0.09	-0.39	-0.58	-0.57	-0.61	-0.08	-0.27	-0.09	-0.2	-82.8	-5.26	11.8	-136	0.15	67.3	22.5	53.1	23.5	14.6	14.8	9.99	-88.3	-30.0	0.82	13.6	-148	9.09	-61.1	50.7	9.02	-10.2
Financing	—	12.5	13.4	89.8	-0.07	151	-1.00	0.19	0.2	0.37	0.67	107	0.55	0.16	0.41	0.17	42.5	3.43	0.43	0.04	45.0	0.05	0.56	7.34	1.72	121	8.16	0.57	1.37	0.55	3.12	92.3	84.3	1.91	70.2
Cash at period end	—	9.55	19.4	105	98.7	243	233	222	211	202	191	287	268	169	149	145	84.1	67.8	113	114	190	192	190	191	179	193	150	128	275	101	83.4	84.2	156	110	107

Profitability

Quarterly · %

Operating margin -686.9% Net margin -654.3%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
Operating margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-826.5%	-781.1%	-934.5%	-831.6%	-479.2%	—	-823.3%	-1055.9%	-673.0%	-607.4%	-613.1%	-60.4%	70.2%	-197.6%	-405.3%	-4382.2%	-857.6%	-701.6%	-686.9%
Net margin	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	-821.6%	-763.0%	-898.8%	-785.0%	-437.6%	—	-741.9%	-962.1%	-625.6%	-531.9%	-540.0%	-46.4%	71.2%	-170.0%	-360.7%	-4132.2%	-802.8%	-660.8%	-654.3%

Returns & leverage

Quarterly · %

ROE -73.6% ROA -63.4% Debt ratio 13.3%

ROE / ROA = trailing four-quarter net income ÷ average equity / total assets (annual mode: the year’s net income ÷ average of opening and closing). Not computed when the denominator is zero or negative.

Show table：Returns & leverage

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
ROE	—	—	—	-11.9%	-29.3%	-16.9%	-20.9%	-19.6%	-24.0%	-19.2%	-22.4%	-20.5%	-23.8%	-29.2%	-35.3%	-34.1%	-36.5%	-40.2%	-45.2%	-50.2%	-43.6%	-50.6%	-54.8%	-60.8%	-61.3%	-47.9%	-52.1%	-45.8%	20.5%	18.2%	15.0%	-2.4%	-45.6%	-61.1%	-73.6%
ROA	—	—	—	-11.6%	—	-8.6%	-11.1%	-19.2%	-17.0%	-18.7%	-21.8%	-19.8%	-23.2%	-28.2%	-33.5%	-32.0%	-31.5%	-34.0%	-37.6%	-40.8%	-33.1%	-37.6%	-40.0%	-43.2%	-44.6%	-36.7%	-39.6%	-35.6%	16.4%	15.2%	12.4%	-2.0%	-39.9%	-53.4%	-63.4%
Debt ratio	—	—	—	2.3%	—	2.0%	2.1%	1.9%	2.9%	3.2%	3.7%	4.0%	2.3%	3.5%	6.4%	8.8%	24.0%	25.6%	26.5%	27.8%	24.1%	26.0%	27.9%	30.1%	31.6%	21.1%	20.9%	15.7%	14.0%	12.9%	14.5%	15.8%	10.9%	12.3%	13.3%

EPS

Quarterly · US$

EPS US$-1.08

Show table：EPS

Item	2018Q1	2018Q2	2018Q3	2018Q4	2019Q1	2019Q2	2019Q3	2019Q4	2020Q1	2020Q2	2020Q3	2020Q4	2021Q1	2021Q2	2021Q3	2021Q4	2022Q1	2022Q2	2022Q3	2022Q4	2023Q1	2023Q2	2023Q3	2023Q4	2024Q1	2024Q2	2024Q3	2024Q4	2025Q1	2025Q2	2025Q3	2025Q4	2026Q1	2026Q2	2026Q3
EPS（US$）	—	—	—	—	—	—	—	—	—	—	—	—	—	-0.60	-0.60	-1.28	-0.66	-0.63	-0.63	-1.31	-0.53	-0.69	-0.55	-0.60	-0.57	-0.46	-0.47	-0.17	1.90	-0.40	-0.65	-0.97	-0.79	-0.93	-1.08

Revenue & profit

Year-to-date · In mn (USD)

Revenue 26.8 mn Net income -185 mn

Year-to-date = summed from the first quarter of the fiscal year; balance-sheet items are period-end balances.

Balance sheet

Year-to-date · In mn (USD)

Total assets 407 mn Total liabilities 54.1 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Cash flow

Year-to-date · In mn (USD)

Operating -180 mn Investing 49.5 mn Financing 156 mn

Positive = cash in, negative = cash out.

Profitability

Year-to-date · %

Operating margin -731.7% Net margin -691.1%

Gross, operating and net margin = the respective profit ÷ revenue.

Returns & leverage

Year-to-date · %

ROE -73.6% ROA -63.4% Debt ratio 13.3%

EPS

Year-to-date · US$

EPS US$-2.80

Revenue & profit

Annual · In mn (USD)

Revenue 184 mn Net income -6.88 mn

Annual = sum of four quarters of a complete fiscal year (incomplete years are omitted); balance-sheet items are year-end balances.

Show table：Income statement

Item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	—	12.4	8.78	36.6	184
Operating income	-12.8	-35.7	-53.0	-86.1	-104	-115	-101	-20.6
Net income	-12.5	-32.3	-52.2	-85.8	-101	-105	-89.0	-6.88

Balance sheet

Annual · In mn (USD)

Total assets 418 mn Total liabilities 66.0 mn

Equity = assets − liabilities. Balance-sheet figures are period-end balances, not cumulative.

Show table：Balance sheet

Item	2018	2019	2020	2021	2022	2023	2024	2025
Current assets	106	226	294	229	244	215	233	306
Total assets	108	229	298	239	256	228	272	418
Current liabilities	2.47	4.10	11.4	17.1	31.4	30.8	40.1	57.9
Total liabilities	2.47	4.32	11.8	21.1	71.2	68.8	42.5	66.0
Equity	105	224	286	218	185	160	229	352

Cash flow

Annual · In mn (USD)

Operating 45.6 mn Investing -187 mn Financing 97.4 mn

Positive = cash in, negative = cash out.

Show table：Cash flow statement

Item	2018	2019	2020	2021	2022	2023	2024	2025
Operating	—	-31.1	-42.2	-66.9	-31.9	-81.1	-86.8	45.6
Investing	—	-1.63	-1.05	-76.4	-45.9	106	-107	-187
Financing	—	150	108	1.28	46.4	53.0	131	97.4
Cash at period end	105	222	287	145	114	191	128	84.2

Profitability

Annual · %

Operating margin -11.2% Net margin -3.7%

Gross, operating and net margin = the respective profit ÷ revenue.

Show table：Profitability

Item	2018	2019	2020	2021	2022	2023	2024	2025
Operating margin	—	—	—	—	-841.3%	-1307.0%	-277.3%	-11.2%
Net margin	—	—	—	—	-814.8%	-1192.3%	-243.4%	-3.7%

Returns & leverage

Annual · %

ROE -2.4% ROA -2.0% Debt ratio 15.8%

Show table：Returns & leverage

Item	2018	2019	2020	2021	2022	2023	2024	2025
ROE	-11.9%	-19.6%	-20.5%	-34.1%	-50.2%	-60.8%	-45.8%	-2.4%
ROA	-11.6%	-19.2%	-19.8%	-32.0%	-40.8%	-43.2%	-35.6%	-2.0%
Debt ratio	2.3%	1.9%	4.0%	8.8%	27.8%	30.1%	15.7%	15.8%

EPS

Annual · US$

EPS US$-0.12

Show table：EPS

Item	2018	2019	2020	2021	2022	2023	2024	2025
EPS（US$）	—	—	—	—	-3.23	-2.37	-1.67	-0.12

Source: SEC EDGAR (XBRL company facts)

Annual reports by year

	10-K
2025	Open full text →
2024	Open full text →
2023	Open full text →

10-K: annual report of a US domestic issuer. Filings are the original documents hosted on SEC EDGAR — this site neither mirrors nor edits them.

FAQ

Where can I read Stoke Therapeutics, Inc. (STOK) annual reports?

Every year in the table above links straight to the full text on SEC EDGAR. US annual reports are web pages (HTML) rather than PDFs, so you can read and search them in the browser without downloading anything. 3 filings are currently indexed.

What is the difference between a 10-K and a 20-F?

A 10-K is the annual report of a US domestic issuer, with sections fixed by law: Item 1 Business, Item 1A Risk Factors, Item 7 Management's Discussion and Analysis. A 20-F is filed by foreign private issuers — Taiwanese companies with US ADRs, such as TSMC, file 20-F rather than 10-K. A 40-F applies to Canadian issuers under the MJDS.

Are earnings call materials available here?

No. Earnings calls are not SEC filings, so US pages on this site cover annual reports only. Taiwan has a mandatory investor-conference disclosure regime, and those materials are indexed under Annual Reports.

Source: US Securities and Exchange Commission (SEC) EDGAR. This site indexes public filings and links to them; it hosts no copies, offers no investment advice, and makes no warranty as to timeliness or completeness.
Back to US annual reports, or see the supply-chain maps.